PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
NCT01248494
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
72
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
BEZ235
DRUG:
BKM 120
DRUG:
Letrozole
DRUG:
BKM120
Sponsor
Vanderbilt-Ingram Cancer Center